Profile
Robert S.
Goodenow held several positions in the pharmaceutical industry, including Principal at Baxter International, Head-Oncology Business Development at Aventis, Secretary & Chief Business Officer at Syndax Pharmaceuticals, and Chief Business Officer at HUYA Bioscience International LLC.
He also served as Vice President-Corporate Development at Inovio Pharmaceuticals, Inc. from 2002 to 2007.
Goodenow received a doctorate from Stanford University and an undergraduate degree from the University of California, Berkeley.
Former positions of Robert Goodenow
| Companies | Position | End |
|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2007-03-15 |
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | President | - |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | - |
| Aventis, Inc. | Corporate Officer/Principal | - |
| SYNDAX PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Training of Robert Goodenow
| University of California, Berkeley | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| BAXTER INTERNATIONAL INC. | Health Technology |
| Private companies | 2 |
|---|---|
| Aventis, Inc. | |
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Robert Goodenow
